1naresh2naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [a07188d2-cc1d-4fcf-a7a8-6c8ca336a956] => Array ( [runtime-id] => a07188d2-cc1d-4fcf-a7a8-6c8ca336a956 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [688c5309-accf-4f9e-866c-2e12a2eb769b] => Array ( [runtime-id] => 688c5309-accf-4f9e-866c-2e12a2eb769b [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;2712e17a7d696b2cd184c7da03951f914831a748 ) ) ) 1naresh2nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [a07188d2-cc1d-4fcf-a7a8-6c8ca336a956] => Array ( [runtime-id] => a07188d2-cc1d-4fcf-a7a8-6c8ca336a956 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [688c5309-accf-4f9e-866c-2e12a2eb769b] => Array ( [runtime-id] => 688c5309-accf-4f9e-866c-2e12a2eb769b [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;2712e17a7d696b2cd184c7da03951f914831a748 ) ) )Table 1:Patient demographics and clinical characteristicsa
Parameter Result (Total n = 131) Age at last scan (mean) (range) (yr) 55.95 (3–86) Sex Male (No.) 58 Female (No.) 73 Indication for imaging Current or prior tumor (No.) 127 Cerebral amyloid angiopathy (No.) 1 Neurosarcoidosis (No.) 1 Progressive multifocal leukoencephalopathy (No.) 1 Recurrent abscesses (No.) 1 Total gadobutrol dose (mean) [SD] (mL) 85.43 [29.20] No. of scans (mean) (range) 12.31 (10–28) Time between first and last scan (median) (range) (mo) 32.4 (2.1–47.2) Lowest eGFR (mL/min/m2) >90 (No.) (range) 22 (90.51–132.26) 60–90 (No.) (range) 59 (60.06–89.75) 45–60 (No.) (range) 34 (45.82–59.83) <45 (No.) (range) 16 (10.16–44.24) Average eGFR (mL/min/m2) >90 (No.) (range) 61 (90.77–145.93) 60–90 (No.) (range) 61 (61.00–89.88) <60 (No.) (range) 9 (38.24–57.26)
↵a No. of scans refers to scans performed with gadolinium contrast.